We are live on ! Find out more
LPC

Lion Point Capital Portfolio holdings

AUM $16.7M
1-Year Est. Return 119.35%
This Fund
S&P 500
This Quarter Est. Return
+8.39%
1 Year Est. Return
+119.35%
3 Year Est. Return
+204.43%
5 Year Est. Return
+220.32%
10 Year Est. Return
+1,396.08%
AUM
$200M
AUM Growth
-$24.6M
Cap. Flow
-$17.4M
Cap. Flow %
-8.71%
Top 10 Hldgs %
93.52%
Holding
34
New
3
Increased
4
Reduced
5
Closed
4

Top Buys

Rank Stock Value
1
MIST icon
Milestone Pharmaceuticals
MIST
+$3.26M
2
SMTC icon
Semtech
SMTC
+$2.32M
3
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
+$1.15M
4
NFYS
Enphys Acquisition Corp.
NFYS
+$827K
5
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$215K

Top Sells

Rank Stock Value
1
DRRX
DURECT Corp
DRRX
+$1.06M
2
BATL icon
Battalion Oil
BATL
+$1M
3
MCRB icon
Seres Therapeutics
MCRB
+$461K
4
MIRM icon
Mirum Pharmaceuticals
MIRM
+$409K
5
ARDX icon
Ardelyx
ARDX
+$112K

Sector Composition

Rank Sector Weight
1 Technology 28.28%
2 Healthcare 13.08%
3 Consumer Discretionary 1.18%
4 Energy 1.07%
5 Financials 0.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SMTC icon
1
Semtech
SMTC
$12.2B
$56.5M 28.26%
2,577,855
+125,000
+5% +$2.32M
SMTC icon
2
CALL
Semtech
SMTC
$12.2B
$54.8M 27.41%
2,500,000
– –
IWM icon
3
PUT
iShares Russell 2000 ETF
IWM
$81.6B
$33.1M 16.57%
165,000
– –
MRNS
4
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$23.2M 11.61%
2,134,337
-11,000
-0.5% -$82.4K
ARDX icon
5
Ardelyx
ARDX
$1.25B
$7.14M 3.57%
1,151,667
-25,000
-2% -$112K
MIST icon
6
Milestone Pharmaceuticals
MIST
$148M
$2.76M 1.38%
1,650,207
+1,200,000
+267% +$3.26M
HARP
7
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$2.6M 1.3%
228,900
+146,442
+178% +$1.15M
BFI
8
DELISTED
BurgerFi International, Inc. Common Stock
BFI
$2.36M 1.18%
2,745,938
– –
KNSA icon
9
Kiniksa Pharmaceuticals
KNSA
$4.85B
$2.29M 1.15%
130,691
– –
INSM icon
10
Insmed
INSM
$23.1B
$2.18M 1.09%
70,335
– –
BATL icon
11
Battalion Oil
BATL
$35.2M
$2.14M 1.07%
222,182
-158,709
-42% -$1M
CBAY
12
DELISTED
Cymabay Therapeutics
CBAY
$1.95M 0.97%
82,425
– –
FENC icon
13
Fennec Pharmaceuticals
FENC
$355M
$1.23M 0.62%
110,000
– –
AVDL
14
DELISTED
Avadel Pharmaceuticals
AVDL
$1.13M 0.57%
80,000
– –
NFYS
15
DELISTED
Enphys Acquisition Corp.
NFYS
$834K 0.42%
+78,125
New +$827K
SNDX icon
16
Syndax Pharmaceuticals
SNDX
$1.84B
$746K 0.37%
34,500
– –
BLUE
17
DELISTED
bluebird bio
BLUE
$733K 0.37%
26,563
– –
TVTX icon
18
Travere Therapeutics
TVTX
$5.31B
$701K 0.35%
78,000
– –
HUMA icon
19
Humacyte
HUMA
$173M
$667K 0.33%
235,000
– –
MCRB icon
20
Seres Therapeutics
MCRB
$49.7M
$477K 0.24%
17,038
-17,552
-51% -$461K
MIRM icon
21
Mirum Pharmaceuticals
MIRM
$6.87B
$399K 0.2%
13,500
-13,500
-50% -$409K
REPL icon
22
Replimune Group
REPL
$837M
$358K 0.18%
42,500
+7,500
+21% +$87K
LUMO
23
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$289K 0.14%
90,794
– –
AMLX icon
24
Amylyx Pharmaceuticals
AMLX
$1.98B
$206K 0.1%
+14,000
New +$215K
WHWK
25
Whitehawk Therapeutics
WHWK
$188M
$166K 0.08%
82,423
– –
1
2

Similar funds

PA
PPM America Chicago, Illinois $16.6M AUM 31.99% 1-Year Est. Return
PA
Prossimo Advisors San Luis Obispo, California $16.4M AUM 14% 1-Year Est. Return
SR
Swiss Re Zurich, Switzerland $16.4M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
SRA
Summit Rock Advisors New York $16M AUM
CP
Covalent Partners Concord, Massachusetts $17.6M AUM 2.91% 1-Year Est. Return
B
BP London, United Kingdom $17.7M AUM 12.34% 1-Year Est. Return
CVV
Curative Ventures V Dallas, Texas $15.6M AUM 52.53% 1-Year Est. Return

Lion Point Capital's Q4 2023 Portfolio in Review

As of Q4 2023, Lion Point Capital held 34 positions worth $200M, down 11% from $224M the previous quarter. Its ten largest holdings account for 94% of the portfolio.

Lion Point Capital withdrew a net $17.4M in Q4 2023, closing 4 positions and reducing 5 holdings. Its most notable exit was DURECT Corp, an estimated $1.06M position sold in full.

By sector, the portfolio is most concentrated in Technology at 28% of assets, up from 28% a quarter earlier, followed by Healthcare and Consumer Discretionary.

Against the trend, Lion Point Capital opened a new position in Enphys Acquisition Corp. worth $834K.

  • Lion Point Capital's largest Q4 2023 buy was Enphys Acquisition Corp.: 78,125 shares worth $834K.
  • Lion Point Capital added most to Milestone Pharmaceuticals in Q4 2023, an estimated $3.26M increase.
  • Lion Point Capital's biggest Q4 2023 reduction was Battalion Oil, cutting an estimated $1M.
  • Lion Point Capital fully exited DURECT Corp in Q4 2023, selling an estimated $1.06M.
  • Lion Point Capital's ten largest holdings make up 94% of its $200M portfolio in Q4 2023.
  • Lion Point Capital opened 3 new positions and closed 4 in Q4 2023.
  • Lion Point Capital's portfolio value fell 11% quarter-over-quarter to $200M.

Based on Lion Point Capital's 13F filing for Q4 2023, filed 14 Feb 2024.